Hongfeng Gou

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 20

Top Topics

Positive Breast Cancer

Positron Emission Tomography

Top Venues

Cancer management and research

This page only lists publications with an associated author ORCID identifier.

Publications

Xiaofen Li, Nan Zhou, Yu Yang, Zijian Lu, Hongfeng Gou
Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer. Cancer science 115 (7) (2024)
Shunyu Zhang, Qiancheng Hu, Xinchuan Chen, Nan Zhou, Qiyue Huang, Sirui Tan, Minggang Su, Hongfeng Gou
68 Ga-FAPI-04 positron emission tomography/CT and laparoscopy for the diagnosis of occult peritoneal metastasis in newly diagnosed locally advanced gastric cancer: study protocol of a single-centre prospective cohort study. BMJ open 14 (4) (2024)
Shunyu Zhang, Qiancheng Hu, Xinchuan Chen, Nan Zhou, Qiyue Huang, Sirui Tan, Minggang Su, Hongfeng Gou
68 Ga-FAPI-04 positron emission tomography/CT and laparoscopy for the diagnosis of occult peritoneal metastasis in newly diagnosed locally advanced gastric cancer: study protocol of a single-centre prospective cohort study. BMJ open 14 (4) (2024)
Xiaofen Li, Nan Zhou, Yu Yang, Zijian Lu, Hongfeng Gou
Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer. Cancer science 115 (7) (2024)
Xiaofen Li, Nan Zhou, Yu Yang, Zijian Lu, Hongfeng Gou
Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer. Cancer science 115 (7) (2024)
Shunyu Zhang, Qiancheng Hu, Xinchuan Chen, Nan Zhou, Qiyue Huang, Sirui Tan, Minggang Su, Hongfeng Gou
68 Ga-FAPI-04 positron emission tomography/CT and laparoscopy for the diagnosis of occult peritoneal metastasis in newly diagnosed locally advanced gastric cancer: study protocol of a single-centre prospective cohort study. BMJ open 14 (4) (2024)
Xiaofen Li, Nan Zhou, Yu Yang, Zijian Lu, Hongfeng Gou
Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer. Cancer science 115 (7) (2024)
Xiaofen Li, Nan Zhou, Yu Yang, Zijian Lu, Hongfeng Gou
Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer. Cancer science (2024)
Shunyu Zhang, Qiancheng Hu, Xinchuan Chen, Nan Zhou, Qiyue Huang, Sirui Tan, Minggang Su, Hongfeng Gou
68 Ga-FAPI-04 positron emission tomography/CT and laparoscopy for the diagnosis of occult peritoneal metastasis in newly diagnosed locally advanced gastric cancer: study protocol of a single-centre prospective cohort study. BMJ open 14 (4) (2024)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Sirui Tan, Shunyu Zhang, Nan Zhou, Xiaohong Cai, Cheng Yi, Hongfeng Gou
Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study. Cancer medicine (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Nan Zhou, Xiaofen Li, Yu Yang, Sirui Tan, Shunyu Zhang, Qiyue Huang, Hongfeng Gou
Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial). BMC cancer 23 (1) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Jing Yu, Xi Zhang, Qiyue Huang, Sirui Tan, Xianze Xiong, Hongfeng Gou
Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy. Cancer management and research 13 (2021)